Creyon
2 known investors
Creyon develops cell-specific therapeutics using aptamer-delivered oligonucleotides and other payloads (lipid nanoparticles, nucleic acids) for immune-driven diseases, CNS conditions, and genetic disorders. The company combines proprietary aptamer delivery technology with an AI-powered nucleic acid engineering platform to enable targeted therapeutic delivery.